CryoPort (CYRX) Stock Price Up 11.4%

Share on StockTwits

Shares of CryoPort Inc (NASDAQ:CYRX) rose 11.4% on Friday . The stock traded as high as $16.00 and last traded at $15.99. Approximately 725,207 shares traded hands during mid-day trading, an increase of 253% from the average daily volume of 205,193 shares. The stock had previously closed at $14.35.

CYRX has been the subject of several recent research reports. ValuEngine raised shares of CryoPort from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 31st. BidaskClub raised shares of CryoPort from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 15th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. CryoPort currently has a consensus rating of “Buy” and a consensus target price of $19.75.

The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.84 and a current ratio of 16.91. The company has a market capitalization of $431.61 million, a price-to-earnings ratio of -51.58 and a beta of 1.10.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Thursday, May 2nd. The consumer goods maker reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $6.65 million during the quarter, compared to the consensus estimate of $6.56 million. CryoPort had a negative net margin of 48.69% and a negative return on equity of 33.40%. The firm’s revenue for the quarter was up 65.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.10) earnings per share. Equities analysts anticipate that CryoPort Inc will post -0.27 EPS for the current fiscal year.

In other CryoPort news, Director Richard J. Berman sold 30,000 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $11.84, for a total value of $355,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 11.00% of the company’s stock.

Several large investors have recently modified their holdings of CYRX. BNP Paribas Arbitrage SA bought a new position in shares of CryoPort during the first quarter valued at about $74,000. Metropolitan Life Insurance Co. NY raised its stake in shares of CryoPort by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,607 shares of the consumer goods maker’s stock valued at $95,000 after acquiring an additional 6,722 shares during the last quarter. MML Investors Services LLC bought a new position in shares of CryoPort during the fourth quarter valued at about $157,000. Bank of America Corp DE raised its stake in shares of CryoPort by 92.3% during the fourth quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock valued at $176,000 after acquiring an additional 7,697 shares during the last quarter. Finally, MetLife Investment Advisors LLC raised its stake in shares of CryoPort by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 18,910 shares of the consumer goods maker’s stock valued at $242,000 after acquiring an additional 6,722 shares during the last quarter. 48.40% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “CryoPort (CYRX) Stock Price Up 11.4%” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://weekherald.com/2019/05/03/cryoport-cyrx-stock-price-up-11-4.html.

CryoPort Company Profile (NASDAQ:CYRX)

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Featured Article: Hedge Funds – Risk or Reward?

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.